| __timestamp | Alpine Immune Sciences, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 12199547 | 3401685 |
| Thursday, January 1, 2015 | 16054000 | 4284228 |
| Friday, January 1, 2016 | 23316000 | 3581295 |
| Sunday, January 1, 2017 | 10626000 | 4838300 |
| Monday, January 1, 2018 | 28970000 | 24891534 |
| Tuesday, January 1, 2019 | 35847000 | 31347891 |
| Wednesday, January 1, 2020 | 27185000 | 17480747 |
| Friday, January 1, 2021 | 58742000 | 34710152 |
| Saturday, January 1, 2022 | 70243000 | 108459978 |
| Sunday, January 1, 2023 | 80904000 | 181563523 |
| Monday, January 1, 2024 | 176326321 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Opthea Limited and Alpine Immune Sciences, Inc. have shown distinct trajectories in their R&D investments over the past decade. From 2014 to 2023, Opthea Limited's R&D expenses surged by over 5,000%, peaking in 2023 with a remarkable 181 million USD. In contrast, Alpine Immune Sciences, Inc. demonstrated a steady increase, with a 560% rise, reaching 81 million USD in 2023. This divergence highlights Opthea's aggressive push in recent years, particularly in 2022 and 2023, where their spending nearly doubled. Such financial strategies underscore the companies' differing approaches to innovation and market positioning. As we look to 2024, Opthea's continued investment remains to be seen, while Alpine's data is yet to be revealed.
Comparing Innovation Spending: Incyte Corporation and Opthea Limited
R&D Insights: How Incyte Corporation and Alpine Immune Sciences, Inc. Allocate Funds
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
BioMarin Pharmaceutical Inc. vs Opthea Limited: Strategic Focus on R&D Spending
Comparing Innovation Spending: Corcept Therapeutics Incorporated and Opthea Limited
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CRISPR Therapeutics AG
Opthea Limited vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How Opthea Limited and Novavax, Inc. Allocate Funds
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc.